II. Indications
- Chemotherapy associated Nausea
- Radiation Therapy associated Nausea
III. Mechanism
- Blocks peripheral and central 5HT3 receptors
- Peripheral 5HT3 receptors at vagal nerve terminals
- Central 5HT3 receptors at ChemoreceptorTrigger Zone in Medulla (area postrema controls Vomiting)
IV. Dosing
-
Nausea with Chemotherapy (adult dosing unless otherwise specified)
- Intravenous (adults and children age >2 years)
- Give 10 mcg/kg IV over 5 minutes given 30 minutes before Chemotherapy
- SQ (Sustol)
- Give 10 mg SQ given 30 min prior to Chemotherapy
- Oral
- Take 2 mg orally once daily OR 1 mg orally twice daily given 1 hour before Chemotherapy
- Transdermal (Sancuso, 34 mg patch delivers 3.1 mg per 24 hours)
- Apply 1 patch to upper outer arm 24 to 48 hours before Chemotherapy
- Remove 24 hours after Chemotherapy (may use 1 patch continuously for up to 7 days)
- Avoid exposing patch to heat or sunlight
- Intravenous (adults and children age >2 years)
-
Nausea with Radiation Therapy (adult)
- Dose: 2 mg orally 1 hour before each Radiation Therapy treatment
V. Adverse Effects
VI. Safety
- Pregnancy Category B
- Unknown safety in Lactation
VII. Resources
VIII. References
- Hamilton (2020) Tarascon Pocket Pharmacopoeia
- Aapro (2004) Oncologist 9(6):673-86 +PMID: 15561811
Images: Related links to external sites (from Bing)
Related Studies
granisetron (on 2/22/2023 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
GRANISETRON HCL 1 MG TABLET | Generic | $2.23 each |
sancuso (on 6/23/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
SANCUSO 3.1 MG/24 HR PATCH | $591.02 each |
Ontology: Granisetron (C0061863)
Definition (NCI_NCI-GLOSS) | The active ingredient in a drug used to treat nausea and vomiting caused by cancer treatment. Granisetron is a type of serotonin receptor antagonist and a type of antiemetic. |
Definition (NCI) | An indazole derivative with antiemetic properties. As a selective serotonin receptor antagonist, granisetron competitively blocks the action of serotonin at 5-hydroxytryptamine3 (5-HT3) receptors, resulting in the suppression of chemotherapy- and radiotherapy-induced nausea and vomiting. |
Definition (MSH) | A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic for cancer chemotherapy patients. |
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | D017829 |
SnomedCT | 108424001, 372489005 |
English | 1H-Indazole-3-carboxamide, 1-methyl-N-(9-methyl-9-azabicyclo(3.3.1)non-3-yl)-, endo-, granisetron, 1-Methyl-N-(9-methyl-endo-9-azabicyclo(3.3.1)non-3-yl)-1H-indazole-3-carboxamide, Granisetron [Chemical/Ingredient], Granisetron Transdermal System, 1-Methyl-N-(endo-9-Methyl-9-Azabicyclo(3.3.1)non-3-yl)-1H-Indazole-3-Carboxamide, GRANISETRON, Granisetron product, Granisetron (product), Granisetron (substance), GRAN, Granisetron |
Swedish | Granisetron |
Czech | granisetron |
Finnish | Granisetroni |
Russian | GRANISETRON, ГРАНИСЕТРОН |
Japanese | グラニセトロン |
Spanish | granisetrón (producto), granisetrona (producto), granisetrona, granisetrona (sustancia), granisetrón (sustancia), granisetrón, Granisetrón |
Polish | Granisetron |
French | Granisétron |
German | Granisetron |
Italian | Granisetrone |
Portuguese | Granisetron |
Ontology: Kytril (C0107189)
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | D017829 |
English | kytril, Kytril |